These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 38101782)

  • 1. [Effectiveness of tofacitinib combined with iguratimod in the treatment of difficult-to-treat moderate-to-severe rheumatoid arthritis].
    Zou X; Bai XJ; Zhang LQ
    Beijing Da Xue Xue Bao Yi Xue Ban; 2023 Dec; 55(6):1013-1021. PubMed ID: 38101782
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Relative efficacy and safety of iguratimod monotherapy for the treatment of patients with rheumatoid arthritis: a systematic review and meta-analysis.
    Shrestha S; Zhao J; Yang C; Zhang J
    Clin Rheumatol; 2020 Jul; 39(7):2139-2150. PubMed ID: 32076916
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Biologics or tofacitinib for people with rheumatoid arthritis unsuccessfully treated with biologics: a systematic review and network meta-analysis.
    Singh JA; Hossain A; Tanjong Ghogomu E; Mudano AS; Maxwell LJ; Buchbinder R; Lopez-Olivo MA; Suarez-Almazor ME; Tugwell P; Wells GA
    Cochrane Database Syst Rev; 2017 Mar; 3(3):CD012591. PubMed ID: 28282491
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effectiveness and Safety of Tofacitinib in Canadian Patients With Rheumatoid Arthritis: Primary Results From a Prospective Observational Study.
    Haraoui B; Khraishi M; Choquette D; Lisnevskaia L; Teo M; Kinch C; Galos C; Roy P; Gruben D; Woolcott JC; Vaillancourt J; Sampalis JS; Keystone EC;
    Arthritis Care Res (Hoboken); 2023 Feb; 75(2):240-251. PubMed ID: 35678771
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tofacitinib versus methotrexate as the first-line disease-modifying antirheumatic drugs in the treatment of rheumatoid arthritis: An open-label randomized controlled trial.
    Khan MM; Ahmed S; Hasan Sajib MK; Morshed AA; Mahbub-Uz-Zaman K; Haq SA
    Int J Rheum Dis; 2023 Sep; 26(9):1729-1736. PubMed ID: 37377385
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biologic or tofacitinib monotherapy for rheumatoid arthritis in people with traditional disease-modifying anti-rheumatic drug (DMARD) failure: a Cochrane Systematic Review and network meta-analysis (NMA).
    Singh JA; Hossain A; Tanjong Ghogomu E; Mudano AS; Tugwell P; Wells GA
    Cochrane Database Syst Rev; 2016 Nov; 11(11):CD012437. PubMed ID: 27855242
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of Glucocorticoids on the Clinical and Radiographic Efficacy of Tofacitinib in Patients with Rheumatoid Arthritis: A Posthoc Analysis of Data from 6 Phase III Studies.
    Charles-Schoeman C; van der Heijde D; Burmester GR; Nash P; Zerbini CAF; Connell CA; Fan H; Kwok K; Bananis E; Fleischmann R
    J Rheumatol; 2018 Feb; 45(2):177-187. PubMed ID: 29142036
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tofacitinib in combination with nonbiologic disease-modifying antirheumatic drugs in patients with active rheumatoid arthritis: a randomized trial.
    Kremer J; Li ZG; Hall S; Fleischmann R; Genovese M; Martin-Mola E; Isaacs JD; Gruben D; Wallenstein G; Krishnaswami S; Zwillich SH; Koncz T; Riese R; Bradley J
    Ann Intern Med; 2013 Aug; 159(4):253-61. PubMed ID: 24026258
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Re-establishment of efficacy of tofacitinib, an oral JAK inhibitor, after temporary discontinuation in patients with rheumatoid arthritis.
    Kaine J; Tesser J; Takiya L; DeMasi R; Wang L; Snyder M; Soma K; Fan H; Bandi V; Wollenhaupt J
    Clin Rheumatol; 2020 Jul; 39(7):2127-2137. PubMed ID: 32048083
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Presence of power Doppler synovitis in rheumatoid arthritis patients with synthetic and/or biological disease-modifying anti-rheumatic drug-induced clinical remission: experience from a Chinese cohort.
    Geng Y; Han J; Deng X; Zhang Z
    Clin Rheumatol; 2014 Aug; 33(8):1061-6. PubMed ID: 24777468
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Iguratimod combination therapy compared with methotrexate monotherapy for the treatment of rheumatoid arthritis: a systematic review and meta-analysis.
    Shrestha S; Zhao J; Yang C; Zhang J
    Clin Rheumatol; 2021 Oct; 40(10):4007-4017. PubMed ID: 33914203
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment outcomes in patients with seropositive versus seronegative rheumatoid arthritis in Phase III randomised clinical trials of tofacitinib.
    Bird P; Hall S; Nash P; Connell CA; Kwok K; Witcombe D; Thirunavukkarasu K
    RMD Open; 2019; 5(1):e000742. PubMed ID: 30886732
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Short-term outcome after anti-tumor necrosis factor-alpha therapy in rheumatoid arthritis: do we need to revise our assessment criteria?
    El Miedany Y; Youssef SS; El Gaafary M
    J Rheumatol; 2006 Mar; 33(3):490-7. PubMed ID: 16511918
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tofacitinib, an oral Janus kinase inhibitor, for the treatment of Latin American patients with rheumatoid arthritis: Pooled efficacy and safety analyses of Phase 3 and long-term extension studies.
    Radominski SC; Cardiel MH; Citera G; Goecke A; Jaller JJ; Lomonte ABV; Miranda P; Velez P; Xibillé D; Kwok K; Rojo R; García EG
    Reumatol Clin; 2017; 13(4):201-209. PubMed ID: 27317492
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of tripterygium glycosides (TG) in rheumatoid arthritis as a disease-modifying anti-rheumatic drug (DMARD) in combination with conventional DMARDs: A systematic review and meta-analysis of randomized controlled trials.
    Feng Z; Fu L; Wang J; Zhu Y; He X; Zhou L; Zhou X
    Pharmacol Res; 2022 Oct; 184():106405. PubMed ID: 36028187
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A prospective observational cohort study of the efficacy of tofacitinib plus iguratimod on rheumatoid arthritis with usual interstitial pneumonia.
    Wang S; Li Y; Tang Y; Xie W; Zhang Y; Liu Q
    Front Immunol; 2023; 14():1215450. PubMed ID: 37680626
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of tofacitinib for the treatment of rheumatoid arthritis in patients from the Asia-Pacific region: Post-hoc analyses of pooled clinical study data.
    Lee EB; Yamanaka H; Liu Y; Tsai WC; Chen C; Kwok K; Yoo HJ; Llamado LJ; Wang L; Luo Y; Sugiyama N; Tanaka Y
    Int J Rheum Dis; 2019 Jun; 22(6):1094-1106. PubMed ID: 30900375
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tofacitinib for the treatment of rheumatoid arthritis: a real-world study in China.
    Shi Y; Xie Y; Zhang G; Feng Y
    Intern Emerg Med; 2022 Apr; 17(3):703-714. PubMed ID: 34559374
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Drug survival and change of disease activity using a second janus kinase inhibitor in patients with difficult-to-treat rheumatoid arthritis who failed to a janus kinase inhibitor and subsequent biologics.
    Kwon OC; Choi W; Ahn SM; Oh JS; Hong S; Lee CK; Yoo B; Park MC; Kim YG
    Adv Rheumatol; 2024 Apr; 64(1):26. PubMed ID: 38622706
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effectiveness and safety of infliximab in rheumatoid arthritis: analysis from a Canadian multicenter prospective observational registry.
    Thorne C; Bensen WG; Choquette D; Chow A; Khraishi M; Atkins CJ; Kelsall JT; Lehman AJ; Shawi M; Khalil H; Nantel F; Rampakakis E; Sampalis JS; Otawa S
    Arthritis Care Res (Hoboken); 2014 Aug; 66(8):1142-51. PubMed ID: 24470077
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.